Trial in Progress: Phase I Study of Actinium-225 (225Ac)-Lintuzumab in Patients with Refractory Multiple Myeloma

被引：8
|
作者：
Levy, Moshe Yair [1 ]
Cicic, Dragan [2 ]
Bergonio, Greory [2 ]
Berger, Mark [2 ]
机构：
[1] Texas Oncol Baylor, Charles A Sammons Canc Ctr, Dallas, TX USA
[2] Actinium Pharmaceut Inc, New York, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-077
引用
收藏
页码：S329 / S330
页数：2
相关论文
共 50 条
  • [1] A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy
    Finn, Laura E.
    Levy, Moshe
    Orozco, Johnnie J.
    Park, Jae H.
    Atallah, Ehab
    Craig, Michael
    Perl, Alexander E.
    Scheinberg, David A.
    Cicic, Dragan
    Bergonio, Gregory Richard
    Berger, Mark S.
    Jurcic, Joseph G.
    BLOOD, 2017, 130
  • [2] A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 μci/Kg/Dose
    Atallah, Ehab L.
    Orozco, Johnnie J.
    Craig, Michael
    Levy, Moshe Yair
    Finn, Laura E.
    Khan, Sharif S.
    Perl, Alexander E.
    Park, Jae H.
    Roboz, Gail J.
    Tse, William
    Begna, Kebede H.
    Mawad, Raya
    Rizzieri, David A.
    Berger, Mark S.
    Jurcic, Joseph G.
    BLOOD, 2018, 132
  • [3] Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)
    Jurcic, Joseph G.
    Levy, Moshe Yair
    Park, Jae H.
    Ravandi, Farhad
    Perl, Alexander E.
    Pagel, John M.
    Smith, B. Douglas
    Estey, Elihu H.
    Kantarjian, Hagop
    Cicic, Dragan
    Scheinberg, David A.
    BLOOD, 2016, 128 (22)
  • [4] Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.
    Jurcic, Joseph G.
    Ravandi, Farhad
    Pagel, John M.
    Park, Jae Hong
    Smith, B. Douglas
    Douer, Dan
    Levy, Moshe Yair
    Estey, Elihu
    Kantarjian, Hagop M.
    Earle, Dennis
    Cicic, Dragan
    Scheinberg, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)
    Jurcic, Joseph G.
    Rosenblat, Todd L.
    McDevitt, Michael R.
    Pandit-Taskar, Neeta
    Carrasquillo, Jorge A.
    Chanel, Suzanne M.
    Zikaras, Kevin
    Frattini, Mark G.
    Maslak, Peter G.
    Cicic, Dragan
    Larson, Steven M.
    Scheinberg, David A.
    BLOOD, 2011, 118 (21) : 348 - 349
  • [6] Trials in Progress: A Phase I/II Study of Venetoclax and Lintuzumab-Ac225 in Patients with Refractory or Relapsed AML
    Hegazi, Mohamed
    Finn, Laura
    Roboz, Gail
    Harpel, John
    Schiller, Gary
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S196 - S196
  • [7] Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)
    Jurcic, Joseph G.
    Ravandi, Farhad
    Pagel, John M.
    Park, Jae H.
    Smith, B. Douglas
    Levy, Moshe Yair
    Estey, Elihu H.
    Perl, Alexander E.
    Kantarjian, Hagop
    Earle, Dennis
    Cicic, Dragan
    Scheinberg, David A.
    BLOOD, 2015, 126 (23)
  • [8] Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)
    Jurcic, Joseph G.
    Ravandi, Farhad
    Pagel, John M.
    Park, Jae H.
    Smith, B. Douglas
    Douer, Dan
    Estey, Elihu H.
    Kantarjian, Hagop M.
    Wahl, Richard L.
    Earle, Dennis
    Cicic, Dragan
    Scheinberg, David A.
    BLOOD, 2014, 124 (21)
  • [9] Trial in Progress: A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
    Jurcic, Joseph G.
    Levy, Moshe
    Park, Jae
    Ravandi, Farhad
    Perl, Alexander
    Pagel, John
    Smith, B. Douglas
    Orozco, Johnnie
    Estey, Elihu
    Kantarjian, Hagop
    Scheinberg, David
    Finn, Laura
    Khan, Sharif
    Hildebrandt, Gerhard
    Craig, Michael
    Atallah, Ehab
    Molina, Irma
    Cicic, Dragan
    Bergonio, Gregory
    Berger, Mark
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S277 - S277
  • [10] Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)
    Jurcic, Joseph G.
    Ravandi, Farhad
    Pagel, John M.
    Park, Jae H.
    Douer, Dan
    Estey, Elihu H.
    Kantarjian, Hagop M.
    Cicic, Dragan
    Scheinberg, David A.
    BLOOD, 2013, 122 (21)
12345